4.6 Article

Differences in subchondral bone size after one year in osteoarthritic and healthy knees

Journal

OSTEOARTHRITIS AND CARTILAGE
Volume 24, Issue 4, Pages 623-630

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.joca.2015.11.004

Keywords

Osteoarthritis; Subchondral bone size; Sensitivity to change; Magnetic resonance imaging

Funding

  1. Pfizer Inc.
  2. Eli Lilly Co
  3. Merck Serono SA
  4. Glaxo Smith Kline Inc.
  5. Wyeth Research
  6. Centocor Research and Development Inc.
  7. Novartis Pharma AG
  8. coordinating center of the OAI at UCSF
  9. Chondrometrics GmbH
  10. National Institutes of Health, a branch of the Department of Health and Human Services [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]
  11. Merck Research Laboratories
  12. Novartis Pharmaceuticals Corporation
  13. GlaxoSmithKline

Ask authors/readers for more resources

Objective: Increase of subchondral bone area (tAB) in OA has been reported, but it remains unclear if this is specific to OA. We investigated differences in knee tAB after one year in healthy subjects and in those with radiographic OA (rOA). Method: MR images of 899 right knees from the OA Initiative were acquired at baseline and one year follow-up (year-1). Medial and lateral tibial cartilage (MT and LT) and weight-bearing femoral cartilage (cMF and cLF) were segmented and tAB computed. Subjects were stratified into: healthy controls, pre-rOA (K&L grades 0 and 1, with OA risk factors), established rOA (K&L grades 2-4), and independently with regards to joint space narrowing (without, with medial, lateral and bilateral JSN). Primary analysis tested if tAB was different between baseline and year-1 in rOA. Exploratory analyses investigated whether: (1) tAB changes differed between healthy controls and those with rOA; (2) tAB differences were greater in higher K&L grades; and (3) tAB was different between baseline and year-1 in JSN. Significance was set at P < 0.0125. Results: Differences in tAB were found in rOA in MT, cMF and cLF (ranging from +0.2% to +0.4%; P < 0.001), but not in healthy controls or pre-rOA. Rates of change did not differ between groups. Within the JSN groups differences of 0.2-0.4% were found in the femur (P < 0.05). Conclusion: We find that knee tABs differ in rOA between baseline and year-1, but the change was not greater than in healthy knees, and is restricted to the femur in JSN. (C) 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available